Maximal care considerations when treating patients with end-stage heart failure: ethical and procedural quandaries in management of the very sick by Ernst R. Schwarz et al.
ORI GIN AL PA PER
Maximal care considerations when treating patients
with end-stage heart failure: ethical and procedural
quandaries in management of the very sick
Ernst R. Schwarz • Kiran J. Philip • Sinan A. Simsir •
Lawrence Czer • Alfredo Trento • Stuart G. Finder •
Laurent A. Cleenewerck
Published online: 27 February 2010
 The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract Deciding who should receive maximal technological treatment options and
who should not represents an ethical, moral, psychological and medico-legal challenge for
health care providers. Especially in patients with chronic heart failure, the ethical and
medico-legal issues associated with providing maximal possible care or withholding the
same are coming to the forefront. Procedures, such as cardiac transplantation, have strict
criteria for adequate candidacy. These criteria for subsequent listing are based on clinical
outcome data but also reflect the reality of organ shortage. Lack of compliance and non-
adherence to lifestyle changes represent relative contraindications to heart transplant
candidacy. Mechanical circulatory support therapy using ventricular assist devices is
becoming a more prominent therapeutic option for patients with end-stage heart failure
who are not candidates for transplantation, which also requires strict criteria to enable
beneficial outcome for the patient. Physicians need to critically reflect that in many cases,
the patient’s best interest might not always mean pursuing maximal technological options
available. This article reflects on the multitude of critical issues that health care providers
have to face while caring for patients with end-stage heart failure.
Keywords Health ethics  Heart failure  Heart transplantation  Ventricular assist devices
The good physician treats the disease; the great physician treats the patient who has
the disease - Sir William Osler
E. R. Schwarz (&)
Division of Cardiology, Cedars Sinai Heart Institute, Cedars Sinai Medical Center,
8700 Beverly Boulevard, Suite 6215, Los Angeles, CA 90048, USA
e-mail: ernst.schwarz@cshs.org
K. J. Philip  S. A. Simsir  L. Czer  A. Trento  L. A. Cleenewerck
Divisions of Cardiology and Cardiothoracic Surgery, Cedars Sinai Heart Institute,
Cedars Sinai Medical Center, Los Angeles, CA, USA
S. G. Finder
Center for Healthcare Ethics, Cedars Sinai Medical Center, Los Angeles, CA, USA
123
J Relig Health (2011) 50:872–879
DOI 10.1007/s10943-010-9326-y
The physician’s task and dilemma
For physicians all over the world, daily practice is guided by and depends on biomedical
sciences and modern technology, which can result in some degree of institutionalized and
depersonalized heath care. However, in spite of the variety of available technological
options and guideline recommendations, physicians know by experience that in many
instances, the best treatment options for a given patient are less than fully clear. Indeed,
optimal care does not necessarily follow the rule of textbooks or recommendations issued
by professional societies. Admitting an ‘uncertainly principle’ in determining the severity
or progression of a condition should lead us to explore the implications of this limitation
with regard to treatment decisions. On the opposite side of the spectrum, physician’s self-
reflection is especially sensitive when an unpredictable chain of events occurs and results
in a catastrophic outcome for the patient despite adequate care.
It is our task as health care providers to provide objective criteria, including the
potential risks and alternatives, so that patients may be in a position to make informed
decisions. In practice, however, patients often lack the knowledge and capacity to make
such decisions completely on their own. The consensus is that it is reflective of good
medical care to be willing to assist patients in this way.
The physician must deal with a unique person and make recommendations that are
suited to the patient’s distinctive characteristics, based on his or her best knowledge and
experience. Especially in the management of patients with ongoing symptoms of heart
failure in spite of maximal medical therapy, it is now recommended to refer patients to
centers with experience in the treatment of advanced stages of heart failure, according to
the recently updated AHA/ACC guidelines (Hunt et al. 2009).
Reasons for not providing maximal care in advanced heart failure
There are several reasons why health care providers may opt not to recommend or provide
maximal care in certain cases. Among a few others, the main reasons health care providers
are challenged within their decision-making process might be categorized as one of two
physician-dependent criteria: therapeutic inertia and lack of resources, or one of two
patient-dependent criteria: lack of compliance and lack of required psycho-social support.
Therapeutic inertia
Therapeutic inertia can be defined as ‘‘the provider’s failure to increase therapy when the
treatment goals are unmet’’ (Okonofua et al. 2006). This has been primarily described in
the treatment and control of blood pressure where health care providers do not always
adopt an aggressive approach to reach the recommended goals (Fine and Jeffrey 2006).
This is typically reflective of situations in which health care providers are unacquainted
with or do not have access to more advanced therapies, but fail to disclose this to patients.
In the context of patients with heart failure, this is often seen outside major medical centers
where the capabilities to provide more advanced therapies such as left ventricular assist
device (VAD) implantation or cardiac transplantation are absent. In particular, multi-organ
transplantations or heart transplantations in patients of older age are rarely discussed with
patients in less specialized centers, especially because many health care providers are
unaware of more specialized therapies and limited acceptance of older recipients (i.e.,
above 65 years of age) for surgical options such as transplantation in ours as well as in
J Relig Health (2011) 50:872–879 873
123
some other medical centers (Blanche et al. 2001). Since the incidence of heart failure is
likely to increase over the coming years with subsequent requirements for physicians to
care for patients with heart failure, more intensive educational activities for cardiologists,
internists and general practitioners are recommended. In addition, the American Board of
Internal Medicine (ABIM) in 2009 established a board sub-specialization for heart failure/
transplant cardiology, and some institutions such as our own have developed fellowship
programs for heart failure specialists cross-trained in cardiology as well as in electro-
physiologic and minimally invasive surgical procedures.
Resource limitations
There are many forms of resource limitations that are in part physician dependent, and in
part contingent on the socio-cultural environment. In the context of cardiac transplantation,
there is a dearth of well-trained transplant physicians and nurses. There is also a lack of
information among health care providers about therapeutic possibilities, requirements for
transplant listing, actual waiting periods and chances to receive an organ for transplanta-
tion, survival rates as well as options of multi-organ transplantation, especially combined
heart-kidney transplantations (Blanche et al. 2001).
Greatest among the resource limitations, however, is the current lack of organs available
for transplantation. As a result, the allocation of organs has been a major point of focus
when considering the ethical dimensions associated with transplant medicine. As part of
these considerations, strict criteria for adequate candidacy prior to listing for cardiac
transplantation have been developed in order to ensure, even before the point of organ
allocation, that only the most suitable candidates are selected (Mandeep et al. 2006). Such
criteria include the existence of social support systems, compliance with medication and
follow-up, as well as abstinence from alcohol, tobacco and other dangerous substances. Of
course, the issue of limited donor supply is quite different from that of limited regional
expertise or limited financial resources. Although both can be expressed in terms of
resource limitation, they require different public and political heath care approaches to
overcome their consequences. Fostering a culture of altruism, with the support of society at
large and of faith communities, has major implications on the development of positive
attitude vis-a`-vis organ donation (Schwarz and Rosanio 2009).
Compliance
The requirement of patient compliance is crucial for therapies whose success greatly
correlates with follow-through. As a result, psycho-social assessment has become an
important part of the evaluation process of potential transplant candidates. Specifically, a
patient’s ability to give informed consent and to comply with instructions including drug
therapy is of paramount importance. In addition, an assessment of support systems
available at home or in the community must be made prior to a patient being accepted for
heart transplantation. In this context, it is observed that conditions such as mental retar-
dation or dementia are typically seen as contraindications, as is evidence of repeat non-
compliance with drug regimen (Mandeep et al. 2006).
Continuous smoking or substance abuse indicates an overall lack of insight into the
requirements of the condition. This typically indicates a bad prognosis, as has been doc-
umented after bypass surgery (Mehta et al. 2008). Poor social support, a family history of
alcoholism and pre-transplantation abstinence of less or equal to 6 months have shown
small but significant associations with relapse of substance abuse after (liver)
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transplantation (Dew et al. 2008). It is also well established that smokers do worse than
non-smokers after heart transplantation (Sa´nchez-La´zaro et al. 2007), also in terms of the
development of renal dysfunction (Sa´nchez La´zaro et al. 2008) as well as malignancies and
reduced graft survival (Botha et al. 2008). For this reason, our center as well as many
others request a minimal period of 6 month abstinence from smoking, and some even
require a contract including acceptance of random blood nicotine (cotinine) level tests.
Existence of adequate psycho-social support
This factor is crucial for long-term outcome after cardiac transplantation, because trans-
plantation surgery requires support outside what health care providers can offer. The
requirements for psychological, emotional and moral attention usually begin with facing a
chronic and debilitating disease long before the day of the surgery but are amplified due to
transplant-related specific matters. The main issues post-cardiac transplantation patients
must cope with include (1) the initial recovery from surgery, (2) the need for life-long
medication usage, (3) frequent repeated office visits, (4) the continuous risk of rejection of
the transplanted organ, (5) the potential of viral, bacterial and fungal infections, (6) the
long-term development of allograft vasculopathy, a transplant-related coronary artery
disease, (7) the risk of development of malignancies, and (8) other co-morbidities that may
impact quality of life. As a result, it is of utmost importance for all transplant candidates to
have access to an effective support system, which will include one or more individuals who
are able to accompany the transplant recipient for follow-up visits, provide transportation,
ensure correct medication usage, provide emotional and social support as well as other
elements deemed necessary for daily living.
Another important aspect related to outcomes is the financial burden many patients face
when dealing with a chronic condition (such as organ transplantation) that requires con-
tinuous medical care and diagnostic assessment. Without financial means or assistance
including adequate insurance coverage proportional to the high cost of immunosuppressant
medications, the mid-term and long-term survival after transplantation is endangered.
Moreover, the involvement of a dedicated social worker is indispensable to provide
psycho-social consultation throughout the evaluation and healing process. A financial
coordinator would also ensure that the patients’ insurance eligibility and benefits are
adequate for transplant candidacy. If, however, this is not the case, the coordinator will
explore such options as obtaining additional coverage or fundraising to cover the patient’s
future transplant expenses.
This evaluation process will support, not undermine, the patient’s autonomy to make a
decision for treatment based on his or her wishes and expectations. On the basis of these
discussions and assessments, the long-term commitment and subsequent burden of post-
transplant requirements might not be the best option for some patients, in which case
alternative therapeutic options should be considered.
Mechanical circulatory assist systems
A therapeutic alternative to either medical therapy or transplantation for the treatment of
end-stage heart failure is the use of mechanical circulatory assist systems, mainly left or
bi-ventricular assist devices (VADs). Recently, the surgical insertion of VADs has
emerged as an applicable possibility for a broader group of patients with advanced stages
of heart failure, especially for those of older age and those with co-morbidities that exclude
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transplantation (Esmore et al. 2008; Long et al. 2008). However, the use of VADs also
requires patient-directed cooperative measures including: (1) the acceptance of having a
mechanical device implanted in the body with an outside driveline requiring maintenance;
(2) the intellectual ability to understand the system and to troubleshoot in case of a device
malfunction; (3) strict adherence to hygienic and medical recommendations in order to
avoid driveline infections that could be fatal; (4) adequate social support to provide all
necessary means to help the patient at home and in the community after leaving the
hospital.
The risks associated with ventricular device implantation can be significantly minimized
with adequate patient cooperation. In particular, the incidence of device-related infections
can be reduced by strict adherence to regular site cleaning procedures performed according
to specific protocols (Zierer et al. 2007).
Altogether, considering a patient for a ventricular assist device—even though not part of
any guideline recommendations, yet—also requires a thorough evaluation of the patients
eligibility, compliance, psycho-social support among other conditions, similar but not
identical to the evaluation process for transplant candidacy.
Unfortunately, in some cases, health care providers might not have enough time for a
detailed assessment such as in cases of sudden cardiogenic shock. In such a situation,
cardiologists and cardiac surgeons have to make decisions based on their initial evaluation
and on the assessment of their peers. In this regard, the insertion of a VAD may sometimes
be considered as a ‘bridge to compliance,’ i.e., as a means to save a person’s life in an
emergent or urgent situation in order to ‘buy time’ to assess compliance for a potential
transplant listing in the future. The ethical implications of such an approach are prob-
lematic, but this procedure is nevertheless adopted in many cases.
Not providing maximal care might in fact mean better care
For a patient to make any decision about the best therapeutic option is rarely easy or ‘clear
cut.’ Often, various treatment opinions exist among different heath care providers or even
between different health care teams within the same provider, which might lead patients
and their families to seek second opinions among different institutions. In order to avoid
misinterpretation of the reasons for treatment decisions and subsequent confusion, it is of
utmost importance for the clinical care team to meet repeatedly with patients to discuss
various options and recommendations. In our institution, we found that it may also be
necessary to regularly re-evaluate the patients’ conditions, decisions and subsequently
discuss possible next steps. In particular, if decisions are based on lack of social support,
encouraging the involvement of individuals such as members of the patient’s family, close
friends and organizations such as religious communities, support groups and other social
communities might in some cases alter the situation and generate the necessary support. In
order to pro-actively promote a sense of mutual responsibility in society, notably in situ-
ations that require exceptional aid, more educational initiatives should be encouraged. This
effort should further be combined with the promulgation of altruistic and humane prin-
ciples of societal co-existence which would be concerned with the unique needs of every
individual member of society.
In general, health care providers should individualize every aspect of the treatment plan
with consideration of all available options and in accordance with treatment goals dis-
cussed with the patients. In addition, the decision from a physician’s point of view whether
or not a person with advanced heart failure is a candidate for more specialized therapies
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such as transplantation or VAD insertion should not depend solely on an initial perception
but rather on a thorough evaluation by a team experienced in the long-term care of such
patients. Even if maximal therapy such as cardiac transplantation or the insertion of an
VAD is a reasonable option, a patient with sound decision-making capacity might still
decide otherwise.
Conservative and palliative care for end-stage heart failure patients
Evidence-based medical drug therapy is the mainstay of treatment for symptom control as
well as reduction of morbidity and mortality for all patients with heart failure. Medical
therapy should always be offered as the first-line option but should not be presented to
patients and their relatives as a last resort when more advanced surgical options are not
suitable. This is even more important in view of the fact that more advanced technological
options, such as heart transplantation or insertion of ventricular assist devices, can be used
to (1) improve symptoms and (2) to prolong life.
According to the World Health Organization (WHO) definition from 2002, palliative
care should be provided early in the course of the disease, in conjunction with other
therapies that are intended to prolong life. Thus, palliative or supportive care should not be
provided in a vacuum as an alternative to other treatment options but rather in the context
of a comprehensive heart failure care model, as outlined in a recent review by Goodlin
(2009). This is especially true in the case of such symptoms as anxiety, depression, chronic
or intermittent pain syndromes, fatigue, dyspnea, sleep disorders, myopathy (possibly
caused by cytokine activation and inflammation as a result of the systemic effects of
ventricular dysfunction) which are usually not assessed in the diagnostic work-up of heart
failure and not directly addressed using common treatment modalities. Palliative care can
help not only with symptom-directed medical therapy such as adequate pain management
but also support emotional and spiritual distress for patients and their caregivers (Bain
et al. 2009). In our program, we involve members of the palliative care service (as well as
spiritual care) at an early stage in the management of our patients.
Ethical considerations
The considerations discussed in this article are bound to raise ethical questions. Is it ever
ethically justifiable to withhold interventions that might potentially prolong life? As
physicians, we are under the obligation to provide—not withhold—medical care. However,
it seems that we must answer affirmatively to the question posed above: it is indeed
justifiable—in certain cases—to withhold interventions that might potentially or theoret-
ically prolong life? Specifically, it appears ethically justifiable to withhold maximal care if
the result would be to adversely impact the patient’s quality of life without curing the
disease or significantly improving the overall condition. In patients with end-stage
malignancies, it appears easier to opt for palliative or hospice care in view of the lack of
curative treatments and because of the context of short life expectancy. For patients with
advanced heart failure, the possible use of palliative and hospice care should be discussed,
including the option of inactivating implanted defibrillators, which has been added to the
recently updated ACC/AHA guidelines for heart failure (Hunt et al. 2009).
Withholding medical treatment without reason is quite different from withdrawing
treatment in very specific end of life situations. However, this distinction and the proper
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means to establish it in practice remains one of the most difficult medico-legal as well as
ethical issues in modern medicine (Ulsenheimer 2008).
Interestingly, ethical issues are dealt with by patients, their families and healthcare
providers quite differently depending on their geographic and religious background
(Hynninen et al. 2008).
In all of these ethical issues, physicians find themselves in the peculiar situation of
having the professional obligation to perform whatever is best for the patient, and this must
be done in the context of shared decision-making. At the same time, health care providers
must refrain from doing whatever might either conflict with the law or at least could raise
legal concerns. As a result, it is incumbent that physicians be familiar not only with the
standards of their professional organizations in terms of acceptable practices, but also with
what the law does and does not prohibit. Especially when taking care of patients with heart
failure, awareness of the various kinds of myths and biases that circulate around end-of-life
decision-making is critical. In addition, these complex issues must be raised before the
patients are in fact reaching their end-of-life state, since prolonged suffering due to
aggressive invasive procedures with complicated recovery versus a life with symptom-
oriented (palliative) therapy and a death with dignity should be discussed. Such discussion
should certainly involve more than just the physician and patient since the implications are
far reaching. Physicians must then be willing to interact with the patient’s family and
spiritual advisors to provide for an adequate decision-making process.
In general, any treatment decision should be based on a profound respect for the
patient’s autonomy balanced by an appreciation of what may be in the patient’s best
interest—the latter itself being deeply nuanced by a wide array of personal, professional,
institutional, spiritual and societal values.
Continuous self-critical reflection of our daily clinical management decisions coupled
with outcome analyses should be part of our routine practice of heart failure and guide our
approach to best address the needs and expectations of patients faced with such extremely
difficult decisions.
Conflicts of interest statement The authors have no conflicts of interest.
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncom-
mercial License which permits any noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
References
Bain, K. T., Maxwell, T. L., Strassels, S. A., & Whellan, D. J. (2009). Hospice use among patients with heart
failure. American Heart Journal, 158, 118–125.
Blanche, C., Blanche, D. A., Kearney, B., Sandhu, M., Czer, L. S., Kamlot, A., et al. (2001a). Heart
transplantation in patients seventy years of age and older: A comparative analysis of outcome. Journal
of Thoracic and Cardiovascular Surgery, 121, 532–541.
Blanche, C., Kamlot, A., Blanche, D. A., Kearney, B., Wong, A. V., Czer, L. S., et al. (2001b). Combined
heart-kidney transplantation with single-donor allograft. Journal of Thoracic and Cardiovascular
Surgery, 122, 495–500.
Botha, P., Peaston, R., White, K., Forty, J., Dark, J. H., & Parry, G. (2008). Smoking after cardiac
transplantation. American Journal of Transplantation, 8, 866–871.
Dew, M. A., DiMartini, A. F., Steel, J., De Vito Dabbs, A., Myaskovsky, L., Unruh, M., et al. (2008). Meta-
analysis of risk for relapse to substance use after transplantation of the liver or other solid organs. Liver
Transplantation, 14, 159–172.
878 J Relig Health (2011) 50:872–879
123
Esmore, D., Kaye, D., Spratt, P., Larbalestier, R., Ruygrok, P., Tsui, S., et al. (2008). A prospective,
multicenter trial of the Ventra Assist left ventricular assist device for bridge to transplant: safety and
efficacy. Journal of Heart and Lung Transplantation, 27, 579–588.
Fine, L. J., & Jeffrey, A. (2006). Cutler hypertension and the treating physician understanding and reducing
therapeutic inertia. Hypertension, 47, 319.
Goodlin, S. J. (2009). Palliative care in congestive heart failure. Journal of the American College of
Cardiology, 54, 386–396.
Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., et al. (2009).
American college of cardiology foundation; American heart association 2009. Focused update incor-
porated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults
a report of the American college of cardiology foundation/American heart association task force on
practice guidelines developed in collaboration with the international society for heart and lung
transplantation. Journal of the American College of Cardiology, 14(53), e1–e90.
Hynninen, M., Klepstad, P., Petersson, J., Skram, U., & Tallgren, M. (2008). Process of foregoing life-
sustaining treatment: a survey among Scandinavian intensivists. Acta Anaesthesiologica Scandinavica,
52, 1081–1085.
Long, J. W., Healy, A. H., Rasmusson, B. Y., Cowley, C. G., Nelson, K. E., Kfoury, A. G., et al. (2008).
Improving outcomes with long-term ‘‘destination’’ therapy using left ventricular assist devices. Journal
of Thoracic and Cardiovascular Surgery, 135, 1353–1361.
Mandeep, R. M., Kobashigawa, J., Starling, R., Russell, S., Uber, P. A., Parameshwar, J., et al. (2006).
Listing criteria for heart transplantation: international society for heart and lung transplantation
guidelines for the care of cardiac transplant candidates—2006. ISHLT, 25, 1024–1042.
Mehta, R. H., Bhatt, D. L., Steg, P. G., Goto, S., Hirsch, A. T., Liau, C. S., et al. (2008). REACH registry
investigators. Modifiable risk factors control and its relationship with 1 year outcomes after coronary
artery bypass surgery: Insights from the REACH registry. European Heart Journal, 29, 3052–3060.
Okonofua, E. C., Simpson, K. N., Jesri, A., Rehman, S. U., Durkalski, V. L., & Egan, B. M. (2006).
Therapeutic inertia is an impediment to achieving the healthy people 2010 blood pressure control
goals. Hypertension, 47, 345–351.
Sa´nchez La´zaro, I. J., Almenar Bonet, L., Martı´nez-Dolz, L., Moro Lo´pez, J., Agu¨ero Ramo´n-Llı´n, J., Cano
Pe´rez, O., et al. (2008). Effect of hypertension, diabetes, and smoking on development of renal
dysfunction after heart transplantation. Transplantation Proceedings, 40, 3049–3050.
Sa´nchez-La´zaro, I. J., Almenar, L., Martı´nez-Dolz, L., Moro, J., Ortiz-Martı´nez, V., Izquierdo, M. T., et al.
(2007). Impact of smoking on survival after heart transplantation. Transplantation Proceedings, 39,
2377–2378.
Schwarz, E. R., Rosanio, S. (2009). Religion and the Catholic Church’s view on (heart) transplantation: a
recent statement of Pope Benedict XVI and its practical impact. Journal of Religion and Health
(in press).
Ulsenheimer, K. (2008). Physician assistance in dying or help to die–a line of legal demarcation (from the
lawyer’s perspective). Z Evid Fortbild Qual Gesundhwes, 102, 176–184.
Zierer, A., Melby, S. J., Voeller, R. K., Guthrie, T. J., Ewald, G. A., Shelton, K., et al. (2007). 9 Late-onset
driveline infections: The Achilles’ heel of prolonged left ventricular assist device support. Annals of
Thoracic Surgery, 84, 515–520.
J Relig Health (2011) 50:872–879 879
123
